Sarepta (SRPT) Q2 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) reported Q2 2026 results on an earnings call. Total revenue was $401.3M, down 34% YoY, with net product revenue $328.7M. Non-GAAP diluted EPS was $0.64. Cash and investments rose to $945.0M. 2026 product revenue guidance was narrowed to $1.2B-$1.3B, and Roche milestone and collaboration revenue were discussed.
How this was made
The 30-second read
Why it matters
Traders can update models using the newly narrowed 2026 guidance ranges, the cash balance change, and the stated FDA PDUFA target date for supplemental NDAs (AMONDYS 45 and VYONDYS 53). The call also flags ELEVIDYS quarter-to-quarter variability and class risks for AAV gene therapy.
Market read
The most tradable elements are the guidance narrowing (product revenue and OpEx), the magnitude of YoY revenue/EPS deterioration, and the explicit regulatory timeline for supplemental approvals.
What to watch
Cash increased by $197M and collaboration guidance was revised upward, which could reduce near-term financing risk and improve risk-adjusted valuation even if Q2 revenue and EPS were weak.
Background
Sarepta’s Q2 2026 earnings call transcript covers financial results, guidance updates, leadership transition to CEO Michael Severino, and upcoming regulatory and clinical milestones.
Ticker impact
Sarepta guided 2026 product revenue to $1.2B-$1.3B and tightened OpEx to $800M-$850M after Q2 revenue fell 34% YoY.
Likely choppy trading with downside risk if investors focus on the revenue decline and ELEVIDYS variability, but support if the narrowed guidance and Roche milestone/collaboration uplift are viewed as stabilizing.
The call discloses multiple decision-relevant datapoints: revenue/EPS deterioration, revised guidance ranges, cash increase, and a specific FDA PDUFA date (Feb. 28, 2027) for supplemental NDAs. However, the transcript excerpt is not a full earnings release and lacks consensus context, limiting precision on magnitude of repricing.
Market effects
Reinforces ongoing volatility in gene-therapy demand and milestone-driven collaboration revenue, which can affect sentiment across rare-disease gene therapy peers.
Primarily US biotech sentiment, with potential spillover to European partners due to Roche milestone and collaboration references.
Roche-linked milestone and contract manufacturing expectations highlight cross-border supply and commercialization dynamics in global gene therapy markets.
Counterpoint
The revenue decline may be more timing-related than fundamental demand collapse, since management cites one-time milestone non-recurrence and points to enrollment-to-infusion conversion that should lift 2027 revenue.
Key entities
- companySarepta Therapeutics, Inc.
Reported Q2 2026 results and narrowed 2026 guidance; discussed ELEVIDYS variability, Roche-related milestone/collaboration, and upcoming FDA PDUFA timing.
- executiveMichael E. Severino
Assumed CEO role and provided commentary on predictive power of preclinical/early clinical data.
- partnerRoche
Referenced for a $40M milestone payment and higher anticipated contract manufacturing revenues affecting collaboration guidance.
- regulatorFDA
Assigned a Feb. 28, 2027 PDUFA target action date for supplemental NDAs seeking traditional approval for AMONDYS 45 and VYONDYS 53.
